

# PEDIATRIC SURGERY Update Vol. 47 No. 06 DECEMBER 2016

## **Undrained Traumatic Hemothorax**

Hemothorax refers as blood in the pleural cavity with the pleural fluid hematocrit being 50% or more of the peripheral blood hematocrit. Hemothorax results after blunt or penetrating trauma to the chest. Spontaneous hemothorax is rare, but can be seen after anticoagulant therapy, pulmonary embolism and pleural malignancy. Emergent management of hemothorax includes management of the associated hemorrhagic shock along with chest tube thoracostomy which in most instances can resolve the problem and expand the compressed lung. Chest tube drainage produces apposition of the pleural surfaces with tamponade of the bleeding vessels, expansion of lung parenchyma and tamponade of lung vessels and drainage of the partially clotted blood. In 5-30% of cases residual hemothorax persists due to clotting of blood within the chest. Up to 40% of these patients will require further surgical intervention for non-resolving. complicated intrapleural collections. empvema or fibrothorax development. A second chest tube is an inadequate alternative in retained hemothorax where initial tube thoracotomy is insufficient. Alternatives of management include open thoracotomy, video-assisted thoracoscopic surgery (VATS), or intrapleural fibrinolysis using streptokinase. Decision making should be based on thoracic CT findings and not simple chest films. VATS is the best available modality for the management of clotted hemothorax as it can clear the chest cavity in 80% of cases avoiding the use of an open thoracotomy. VATS can cause complications in 10% of patients such as transient hypoxemia, arrhythmia, intercostal neuritis, chest wall bleeding or iatrogenic lung injury. Another available alternative that has gained wide world acceptance is intrapleural fibrinolytic therapy using streptokinase or urokinase with a success rate of 90%. The use of intrapleural streptokinase does not cause significant fibrinolysis and is unlikely to cause systemic bleeding. Fibrinolytic agents appear to have a role in managing retained hemothorax with significant clinical and radiological improvement and should be used as initial management of retained hemothorax.

#### **References:**

1- Agarwal R, Aggarwal AN, Gupta D: Intrapleural fibrinolysis in clotted haemothorax. Singapore Med J. 47(11):984-6, 2006

2- Hunt I, Thakar C, Southon R, Bedard EL: Establishing a role for intra-pleural fibrinolysis in managing traumatic haemothoraces. Interact Cardiovasc Thorac Surg. 8(1):129-33, 2009

3- Vassiliu P, Velmahos GC, Toutouzas KG: Timing, safety, and efficacy of thoracoscopic evacuation of undrained post-traumatic hemothorax. Am Surg. 67(12):1165-9, 2001

4- Velmahos GC(1), Demetriades D, Chan L, Tatevossian R, Cornwell EE 3rd, Yassa N, Murray JA, Asensio JA, Berne TV: Predicting the need for thoracoscopic evacuation of residual traumatic

hemothorax: chest radiograph is insufficient. J Trauma. 46(1):65-70. 1999

5- Kumar S, Rathi V, Rattan A, Chaudhary S, Agarwal N: VATS versus intrapleural streptokinase: A prospective, randomized, controlled clinical trial for optimum treatment of post-traumatic Residual

Hemothorax. Injury. 46(9):1749-52, 2015

6- Kimbrell BJ, Yamzon J, Petrone P, Asensio JA, Velmahos GC: Intrapleural thrombolysis for the management of undrained traumatic hemothorax: a prospective observational study. J Trauma. 62(5):1175-8, 2007

## Growing Teratoma Syndrome

Ovarian or testicular teratomas are either mature (most commonly), immature or malignant. The immature and malignant teratomas can secrete alpha fetoprotein (AFP) and/or human chorionic gonadotropin (HCG). Immature teratomas are potentially malignant and as such will need chemotherapy to change the features of immaturity into mature teratoma and reduce the level of tumor markers. Teratomas that increase in size during or after chemotherapy as tumor marker levels decrease is known as growing teratoma syndrome (GTS). By definition GTS includes normalization of previously elevated serum tumors markers (AFP or HCG), an increase in tumor size during or after chemotherapy given for non-seminomatous germ cell tumor and an absence of such components other than mature teratoma at resection. GTS is characterized by an absence of malignant germ cell components as the growing tissue is benign. Further chemotherapy is unable to shrink GTS. The radiological features include increased density of mass with well-circumscribed margins, onset of internal calcification with fatty areas and cystic changes. Retroperitoneum is the most common site for GTS. Pathogenesis of development of GTS is either malignant cell differentiation into mature teratoma or selective chemotherapy induced destruction of immature elements. Complete surgical excision of the mass is required to avoid pressure effects and potential malignant transformation to either sarcoma or carcinoma. Pressure effect of the growing tumor includes vascular thrombosis, ureteral obstruction, bowel obstruction, bile duct obstruction and fecal fistula. Malignant transformation to sarcoma, adenocarcinoma or PNET is reported in 3% of cases. Alpha-2-Interferon can control disseminated unresectable GTS by inhibiting tumor angiogenesis mediated by decreased level of vascular endothelial growth factor and basic fibroblast growth factor, but the regression is slow, incomplete and discontinuation results in progression of disease. Prognosis after complete surgical resection is excellent.

#### **References:**

1- Hsieh YL, Liu CS: Progression from an immature teratoma with miliary gliomatosis peritonei to

growing teratoma syndrome with nodular gliomatosis peritonei. Pediatr Neonatol. 50(2):78-81, 2009

2- Sengar AR, Kulkarni JN: Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma. J Gynecol Oncol. 21(2):129-31, 2010

3- Li S, Liu Z, Dong C, Long F, Liu Q, Sun D, Gao Z, Wang L: Growing Teratoma Syndrome Secondary to Ovarian Giant Immature Teratoma in an Adolescent Girl: A Case Report and Literature Review. Medicine (Baltimore). 95(7):e2647, 2016

4- Daher P, Riachy E, Khoury A, Raffoul L, Ghorra C, Rehayem C: Growing teratoma syndrome: first case report in a 4-year-old girl. J Pediatr Adolesc Gynecol. 28(1):e5-7, 2015

5- Zagama L, Pautier P, Duvillard P, Castaigne D, Patte C, Lhomma C: Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol. 108(3 Pt 1):509-14, 2006

6- Tangjitgamol S, Manusirivithaya S, Leelahakorn S, Thawaramara T, Suekwatana P, Sheanakul C: The growing teratoma syndrome: a case report and a review of the literature. Int J Gynecol Cancer. 16 Suppl 1:384-90, 2006

7- Nimkin K, Gupta P, McCauley R, Gilchrist BF, Lessin MS: The growing teratoma syndrome. Pediatr Radiol. 34(3):259-62, 2004

## **Epiploic Appendagitis**

Epiploic appendages are peritoneum-covered fat outpouches protruding from the serosal antimesenteric border of the taeniae of the large bowel, except in the rectum. Blood supply of the epiploic appendages is derived from a single artery and vein located within the pedicle. Epiploic appendagitis occur when there occurs either torsion and/or infarction of the appendage. Epiploic appendagitis is an uncommon cause of acute abdominal pain in children and adults manifesting most commonly in the fourth or fifth decade of life with male predominance. Mostly epiploic appendagitis involve the sigmoid colon and the pain can be mistaken for diverticulitis. When it involves the cecum it can mimics appendicitis. With the widespread use of CT-Scan in the diagnosis of abdominal pain in children, epiploic appendagitis is commonly diagnosed before operation is undertaken for an acute abdomen. In US the appendagitis shows a noncompressible hyperechoic mass near the colonic wall at the point of maximum tenderness, absence of changes in the colon wall and absence of color flow on Doppler. CT-Scan findings include an oval lesion with attenuation similar to fat surrounded bu a hyperattenuated ring located near but distinct to the colon, inflammatory changes in the surrounding fat and absence of other abnormalities. The presence of a central hyperdense dot thought to represent a thrombosed vein to the epiploic appendix is a specific sign felt to distinguish epiploic appendagitis from omental torsion. MRI findings of epiploic appendagitis include an oval-shaped lesion, usually one to 4 cm in size, with high signal intensity center and low signal intensity rim on T1-weighted images. Obesity seems a risk factor. If the diagnosis of epiploic appendagitis is made preoperative with certain degree of confidence management can be conservative using pain killers. Most children recover in ten days. If the diagnosis is uncertain then laparoscopy has been found to be effective in diagnosis and management of epiploic appendagitis.

#### **References:**

1- Fraser JD, Aguayo P, Leys CM, St Peter SD, Ostlie DJ: Infarction of an epiploic appendage in a pediatric patient. J Pediatr Surg. 44(8):1659-61, 2009

2- Rashid A, Nazir S, Hakim SY, Chalkoo MA: Epiploic appendagitis of caecum: a diagnostic dilemma. Ger Med Sci. 10: 1612-3174, 2012

3- Toprak H, Yildiz S, Kilicarslan R, Bilgin M: Epiploic appendagitis. JBR-BTR. 97(3):174-5, 2014

4- Cho MS, Hwang-Bo S, Choi UY, Kim HS, Hahn SH: A case of epiploic appendagitis with acute gastroenteritis. Pediatr Gastroenterol Hepatol Nutr. 17(4):263-5, 2014

5- Redmond P, Sawaya DE, Miller KH, Nowicki MJ: Epiploic Appendagitis: A Rare Cause of Acute Abdominal Pain in Children. Report of a Case and Review of the Pediatric Literature. Pediatr Emerg Care. 31(10):717-9, 2015

6- Boscarelli A, Frediani S, Ceccanti S, Falconi I, Masselli G, Casciani E, Cozzi DA: Magnetic resonance imaging of epiploic appendagitis in children. J Pediatr Surg.(on line) http://dx.doi.org/10.1016/j.jpedsurg.2016.09.052

### \*Edited by: Humberto Lugo-Vicente, MD, FACS, FAAP

Professor of Pediatric Surgery, University of Puerto Rico - School of Medicine, Rio Piedras, Puerto Rico. Director - Pediatric Surgery, San Jorge Childrens Hospital. Address: P.O. Box 10426, Caparra Heights Station, San Juan, Puerto Rico USA 00922-0426. Tel (787)-999-9450 Fax (787)-720-6103 E-mail: *titolugo@coqui.net* Internet: http://home.coqui.net/titolugo

© PSU 1993-2016 ISSN 1089-7739